Despite recent advances in the treatment of ATTR and AL amyloidosis, one major goal remains—the effective clearance of tissue amyloid from organs, which may foster the recovery of organ function and improvement in patient outcomes and quality of life. The gene discussed is TTR; the disease is AL amyloidosis.